Contact us (is on the right)

  1. Company
    1. About
    2. Services
  2. Media
    1. News blog
    2. Meet GCT team
  3. White papers
    1. Region and countries
    2. Therapeutic areas
  4. Services
    1. Site registration
    2. Patient information Center
  5. Website information
    1. Privacy policy
    2. Terms of service
    3. Site map
    4. Employees login

Get in touch

Call us:

Email: info@gctrials.com

Meet us at upcoming industry events

More: Offices, Career at GCT

Patients: Patient information Center

CRO Contract Research Organization with 15+ years expertise in Russia, Central and Eastern Europe


FDA/EMEA/GCP compliant clinical trials in all therapeutic areas, phases I-IV

Phase I-IV clinical trials conducted since 2001

Over 15,000 subjects enrolled

Excellence at enrollment

Projection vs actual enrollment for one of our recent studies

Trusted clinical data

Over 2/3 of all FDA/EMA approved drugs are studied in international trials involving Russia

Shortest regulatory timelines

Our regulatory track is 100% successfull

Headquarters in Princeton, NJ, USA

Six regional offices in CEEcovering Bulgaria, Czech Republic, Hungary, Romania, Russia, Slovakia and Ukraine

Explore coverage details

Head office, BD office
Princeton, NJ, USA

Phone: 1-609-921-6868
Contact details

Russian office, BD office in St. Petersburg

Phone: 7-812-703-0008
Country information
Contact details

Ukrainian office in Kiev

Phone: 38-044-501-9038
Country information
Contact details

Romanian office in Bucharest

Phone: 40-21-527-0380
Country information
Contact details

Bulgarian office in Sofia

Phone: 359-2-983-5358
Country information
Contact details

Central Europe office in Budapest

Phone: 36-30-353-7538
Hungary information
Czech Republic information
Slovakia information
Contact details

A full-service CRO

We will have you covered end-to-end throughout the trial

  • Study start-up
  • Regulatory services
  • Global, regional, local project management
  • Local safety, medical monitoring support
  • Clinical monitoring
  • Patient recruitment
  • Drug logistics
  • Data management and biostatistics
See a detailed list of our services

In the news

See all news

July 27, 2017

GCT expands clinical operations to Poland

GCT announced a new office opening in Warsaw, Poland

 

Following the direction set last year when GCT established clinical operations in three new countries – Hungary, Czech Republic, and Slovakia, – in May 2017 the company moved further into Central Europe and opened an office in Warsaw, Poland. GCT presently offers its clients full assistance for clinical trials conduct in Poland, including feasibility studies, clinical monitoring, study management, and regulatory support.

July 26, 2017

Strengthening GCT ophthalmic experience

GCT team in Budapest has started trainings for the newest ophthalmic project which we were recently awarded by our long-term partners. The study is an EU multinational Phase II clinical trial involving patients with diabetic macular edema.

We are delighted to demonstrate our expertise in clinical research within eye diseases field yet again. Our previous experience includes such indications as subfoveal choroidal neovascularization in subjects with pathologic myopia, diabetic retinopathy, age-related macular degeneration, open-angle glaucoma, ocular hypertension, dry eye symptoms after refractive surgery, and others.

July 14, 2017

Benign Prostatic Hyperplasia study award

Inventive device, designed to provide permanent relief of the obstructions in patients with prostatic enlargement, will be tested in Slovakia. GCT is eager to apply and deepen our expertise in managing Urology and Medical Devices clinical trials in EU.

Benign prostatic hyperplasia (BPH) is a common condition in men 50 years and older that can be clinically observed as lower-urinary tract symptoms. There are several treatment options that include pharmacotherapy, minimally invasive therapies and surgery. The gold standard for surgical intervention has been transurethral resection of the prostate (TURP), but in recent years, as technology emerges, men tend to choose those less invasive options with fewer side-effects and morbidity. The new investigative prostate retraction device is intended to reduce most of the known side effects and complications caused by the usage of urethral stents.

Meet GCT team

Hear our clients

The management team and the CRAs are physicians, and the lead monitor for our breast cancer trial is an oncologist. The monitoring and reporting of the data are exceptional.

Senior Director, Clinical Operations,
US Pharma